AbbVie (ABBV) Seeks FDA Approval For Etentamig In Multiple Myeloma

{
  "signal_id": "ee770516-d21e-9577-c073-0b0c600b9d3e",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-28T16:16:42+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-seeks-fda-approval-161642787.html",
    "title": "AbbVie (ABBV) Seeks FDA Approval For Etentamig In Multiple Myeloma - Yahoo Finance",
    "ticker": "NYSE:ABBV",
    "excerpt": "AbbVie (NYSE: ABBV) has submitted a Biologics License Application to the FDA for its multiple myeloma candidate etentamig. The filing is backed by a pivotal Phase 3 trial in relapsed or refractory multiple myeloma that met its primary endpoint. Etentamig is a second generation BCMA x CD3 bispecific antibody that is administered on a monthly dosing schedule. There is more to AbbVie than the new etentamig BLA, starting with other oncology and immunology efforts. We have also flagged 4 warning signs for AbbVie. For readers looking beyond AbbVie to more ways oncology research and automation intersect, explore the broader opportunity set at 34 healthcare AI stocks . AbbVie operates as a global research-focused biopharmaceutical group, and this etentamig filing fits into its broader push in oncology alongside an established presence in immunology therapies. The business uses its large-scale research, manufacturing, and commercial network to move late-stage drug candidates toward potential worldwide use. 3 things going right for AbbVie that this headline doesn't cover. For AbbVie investors, the etentamig BLA lines up cleanly with the existing Narrative that oncology is one of the key levers that needs to pick up more of the slack as Humira and Imbruvica face pressure. Strong Phase 3 data in a triple class exposed multiple myeloma group, coupled with a monthly dosing schedule and a...",
    "product": "etentamig",
    "summary": "AbbVie submitted a Biologics License Application to the FDA for its multiple myeloma drug candidate etentamig.",
    "planning": false,
    "image_url": "https://s.yimg.com/lo/mysterio/api/f5712766f9839de6aac29aee3b8cef90c05bf7bfdf209767944700c7df173a11/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fsimply_wall_st__316%2F8bb05c0ff7538d04db7665c8b8ba3b25.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "etentamig",
      "full_text": "multiple myeloma candidate etentamig",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-28T16:16:42Z",
    "article_sentence": "AbbVie (NYSE: ABBV) has submitted a Biologics License Application to the FDA for its multiple myeloma candidate etentamig."
  }
}

curl https://signals.autobound.ai/v1/signals/ee770516-d21e-9577-c073-0b0c600b9d3e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'